Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Author:Rindner, Elisabeth   Mahdavi, Kennedy   Haroon, Jonathan   Jordan, Kaya   Zielinski, Margaret   Venkatraman, Victoria   Surya, Jean   Goodenowe, Dayan   Ahlem, Clarence   Reading, Christopher   Palumbo, Joseph   Pourat, Bijan   Jordan, Sheldon   

Session Name:P8: Aging and Dementia: Therapeutics 2  

Topic:Aging and Dementia  

Program Number:P8.007  

Author Institution:The Regenesis Project, Santa Monica, CA  Prodrome Sciences USA LLC, Temecula, CA  BioVie Inc., Carson City, NV  Pourat MD, Beverly Hills, CA  

Diagnostic Yield of Extended Cardiac Patch Monitoring in Cryptogenic Stroke Patients

Author:Rice, Victoria   Lucioni, Tomas   Aiello, Gregory   Ranasinghe, Tamra   Thorson, Justin   

Session Name:P11: Cerebrovascular Disease and Interventional Neurology: Neuroimaging and Secondary Stroke Prevention  

Topic:Cerebrovascular Disease and Interventional Neurology  

Program Number:P11.032  

Author Institution:Wake Forest Baptist Medical Center, Winston Salem, NC  Wake Forest Baptist Health, Winston Salem, NC  

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial

Author:Goadsby, Peter J.   Ailani, Jessica   Dodick, David W.   J. Starling, Amaal   Liu, Chengcheng   Yu, Sung Yun   Brand-Schieber, Elimor   Finnegan, Michelle   M. Trugman, Joel   

Session Name:S47: Advances in Migraine Therapeutics  

Topic:Headache  

Program Number:S47.002  

Author Institution:King's College and University of California Los Angeles, London, United Kingdom  Medstar Georgetown Neurology, McLean, VA  Mayo Clinic, Phoenix, AZ  AbbVie, Madison, NJ  

Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial

Author:Pozo-Rosich, Patricia   Ailani, Jessica   Ashina, Messoud   Goadsby, Peter   Lipton, Richard   Reuter, Uwe   Guo, Hua   Schwefel, Brittany   Boinpally, Ramesh   McCusker, Emily   Yu, Sung Yun   Finnegan, Michelle   Trugman, Joel   

Session Name:S47: Advances in Migraine Therapeutics  

Topic:Headache  

Program Number:S47.005  

Author Institution:Vall d’Hebron University Hospital & Vall d’Hebron Institute of Research, Universitat Autonoma of Barcelona, Barcelona, Spain  Georgetown Headache Center, Georgetown University Hospital, McLean, VA  Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark  NIHR-Wellcome Trust King's Clinical Research Facility, King's College London & University of California, Los Angeles, CA  Albert Einstein College of Medicine, Bronx, NY  Department of Neurology, Charité-Universitätsmedizin Berlin & Universitätsmedizin Greifswald, Berlin, Germany  AbbVie, Madison, NJ  AbbVie, North Chicago, IL  AbbVie, Madison , NJ  

Responder Rates With Eptinezumab Over 24 Weeks in Patients With Prior Migraine Preventive Treatment Failures

Author:Ashina, Messoud   Lipton, Richard B   Ailani, Jessica   Versijpt, Jan   Sacco, Simona   Mitsikostas, Dimos D   Christoffersen, Cecilie   Sperling, Bjorn   Ettrup, Anders   

Session Name:S47: Advances in Migraine Therapeutics  

Topic:Headache  

Program Number:S47.007  

Author Institution:Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark  Department of Neurology, Albert Einstein College of Medicine, Bronx, NY  Department of Neurology, Georgetown University Hospital, Washington DC, WA  Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Neurology, Brussels, Belgium  Department of Biotechnological and Clinical Sciences, University of L’Aquila, L'Aquila, Italy  1st Department of Neurology, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece  H. Lundbeck A/S, Copenhagen, Denmark